On a magic taxi ride. Well, you don't know what we can see. Why don't you tell your dreams to me. Fantasy will set you free...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HoD 2.05 tells the story of where this is heading.
"The convertible debentures mature after one year." Good to know we will be spared any dilutive effect from that for at least a year.
Cleaning up debt here has proven to be a strong move for $IMTV.
$IMTV has got some great news up its sleeve yet to be announced soon IMHO.
Yeah LiveNation has 1 third of the $30 Billion in revs that the concert promotion business brought in .
2 revenue producing concerts in a row. $IMTV is looking better and better!
Looking for a big autumn here for OXS1550
OXS-1550:
OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. CD19 is a membrane glycoprotein present on the surface of all stages of B-lymphocyte development, and is also expressed on most B-cell mature lymphoma cells and leukemia cells. CD22 is a glycoprotein expressed on B-lineage lymphoid precursors, including precursor acute lymphoblastic leukemia, and often is co-expressed with CD19 on mature B-cell malignancies such as lymphoma.
OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550, and are killed due to the action of drug’s cytotoxic diphtheria toxin payload. OXS-1550 has demonstrated success in a Phase 1 human clinical trial in patients with relapsed/refractory B-cell lymphoma or leukemia.
Im a little disgruntled to see it just dip under $2 here. But the GTBP support is resillient and I expect to see it reaasert itself at open tommorow.
The video I watched she said she was taking jogs around the lake while being treated with oxs 1550! Thats nothing at all like the debilitating process involved with normal chemotherapy.
Current Phase 2 results for OXS 1550 shows 14 out of 17 patients showed a clinical benefit. Thats astonishing! In the best possible way.
The recent admin team reshuffling though looks to be good for the future of this ticker.
OXS 3550 should revoutionize industry state of the art in solid tumor therapies.
GTBP lets see if we can end over 2.
$IMTV: non-diliutive revs anyone?
LiveNation trades at $49 on the NYSE and took in $10 Billion in revenues last year.
A Cuban music festival could be huge in Miami.
$IMTV wonder when we can work up to a big arena show?
Exactly. Partnerships here are much more key than in other sectors. In concert promotion it really is about who you know. $IMTV knows that value and they are excelling at building their network.
Great update:
Yeah we are getting some hints but can you imagine what they will stage to level up after LIT UP Fest? Its going to be HUUUGE!
Juice Wrld rocking it at LIT UP Fest. This kid has a bright future:
$IMTV really created a ripple effect when they sold out the LIT Up music festival. A stable of platinum selling artists now knows that IMTV can take care of business and they will spread the buzz to there network.
GTBP the next OXS 1550 announcement could really catalyze the next move up. Getting ready.
Notable GTBP Milestones:
• Applied for NASDAQ uplisting
• OXS-3550 Activity
? IND filing - mid-2018
? First in-human clinical trials – 2H:18
• OXS-1550 data readout – 2H:18
• TetraKE pre-clinical work – 4Q18-1Q
Combination Therapies hold out a big possibility for a major buy-out:
OXS 1550 can actually target the leukemia and lymphoma cells to to deliver a diptheria toxin and discern to not attack healthy cells. Simply amazing $GTBP
Conventional cancer treatment has not changed significantly in 40 years. But OXS 1550 and OXS 3550 should shake all that up as we get out of testing and head to market. Awesome for $GTPB holders.
No wonder the unnamed multi Bilion $ BioPharma stepped in and wanted to be involved in testing.
TriKE biotechnology is the latest and greatest innovation coming down the Immmuno Oncology pike:
Concert promotion is a $30 billion plus behemoth on the USA enteratinment scene. Who would have guessed, but its true! If you watch $IMTV's last 2 concert partnerships closely you can tell they are not random choices, but carfully planned chess board movements to be positioned to corner this sector.
Yeah its truly the definition of an undiscovered gem.
Strong strategy forming here: "Juan Areco, CEO of Imagination TV commented, "Based on the success from our 1st co-produced event LIT Up Music Festival it seemed to be a natural evolution that our relationship would continue. We have learned so much from everyone at Nine Mile and look forward to what the future brings."
Its interesting that we know now that there will be two more collaborations with Nine Mile presumably in the hip hop space. However that doesnt even mean that this next concert in September need necessarily be a hip hop concert. Still open to debate IMHO.
I'm expecting to hear $IMTV heard in the same breath more and more along with HIp Hop headliners. Nationwide notoriety should keep growing.
Definitely $IMTV loading zone here today! LIke taking candy from a baby LOL.
Nine Mile entertainment is an incredibly valuable parnership for a new venture like $IMTV. Family run by non other than the family and friends of departed Bob Marley, and situated right in the center of Dirty South Hip Hop central, the kind of exposure and connections that IMTV can leverage out of the relationship is nothing short of priceless.
Looking for a strong opening tommorow. Right past todays 2.18 HOD. $GTBP is on the recovery.
Agreed. All we need is for some more solid news to get some awareness. Perhaps we'll hear about an OXS 1550 buyout offer soon. Possibly from that billion dollar biopharma that is testing their successful therapy alongside OXS1550.
Precisely. And we can further infer from that fact then that this nice entry level price won't be around very long. Get em while they're hot boys!